{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:26:17Z","timestamp":1787635577842,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jid.2017.10.030","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T21:47:23Z","timestamp":1510264043000},"page":"795-801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["MABp1 Targeting IL-1\u03b1 for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study"],"prefix":"10.1016","volume":"138","author":[{"given":"Theodora","family":"Kanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Argyropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistoklis","family":"Spyridopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Pistiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2017.10.030_bib1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ni.3503","article-title":"Interleukin 1\u03b1 and the inflammatory process","volume":"17","author":"Di Paolo","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2017.10.030_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2017.10.030_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib4","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jid.2016.04.021","article-title":"High copy numbers of \u03b2-defensin cluster on 8p23.1, confer genetic susceptibility, and modulate the physical course of hidradenitis suppurativa\/acne inversa","volume":"136","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2017.10.030_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of score outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process","volume":"175","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib7","doi-asserted-by":"crossref","first-page":"e0130522","DOI":"10.1371\/journal.pone.0130522","article-title":"Compartmentalized cytokine responses in hidradenitis suppurativa","volume":"10","author":"Kanni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2017.10.030_bib8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/ijd.12550","article-title":"Hidradenitis suppurativa: the role of immune dysregulation","volume":"53","author":"Kelly","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2017.10.030_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab in hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2017.10.030_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"R\u00e9vuz","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2017.10.030_bib13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","article-title":"Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies","volume":"59","author":"R\u00e9vuz","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/0006-2952(93)90429-Z","article-title":"Agonist-stimulated Cl- efflux from human neutrophils. A common phenomenon during neutrophil activation","volume":"45","author":"Shimizu","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jid.2017.10.030_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"A\u00a0randomized clinical study of the safety and efficacy of anakinra in severe hidradenitis suppurativa","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2017.10.030_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17331470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17331470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T05:01:26Z","timestamp":1542949286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X17331470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0022202X17331470"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2017.10.030","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MABp1 Targeting IL-1\u03b1 for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2017.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}